Switch to
More onapp

Cadila Healthcare Ltd

ZYDUSLIFE
Health CarePharmaceuticals
MidcapWith a market cap of ₹40,460 cr, stock is ranked 129
Low RiskStock is 1.56x as volatile as Nifty
415.504.35 (+1.06%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
MidcapWith a market cap of ₹40,460 cr, stock is ranked 129
Low RiskStock is 1.56x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
9.02
PB RatioPB Ratio
2.12
Dividend YieldDiv. Yield
0.63%
Sector PESector PE
35.90
Sector PBSector PB
4.36
Sector Div YldSctr Div Yld
0.88%

Forecast & RatingsDetailed Forecast 

47%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Cadila Healthcare Limited is an India-based pharmaceutical company. The Company operates through two segments: Pharmaceuticals and Consumer Products. The Pharmaceuticals segment represents the business of integrated pharmaceutical operations with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The Company’s product portfolio includes the active pharmaceutical ingredients (API), human formulations, and animal health and veterinary. The Consumer Products segment represents the business of development, production, marketing and distribution of differentiated health and wellness products. The Company has a global presence and sells its products in the United States, India, Europe and other markets, including countries in Latin America, Asia Pacific region and Africa.

Brands

Cadila

Pharmaceutical company

Zydus Cadila

Investor PresentationView older 

Nov 11, 2022

PDF
View Older Presentations

Brands

Cadila

Pharmaceutical company

Zydus Cadila

Financial TrendFinancial statements 

201920202021202213.3714.3714.4517.851.851.182.134.49
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Related Party Transaction 
Announced OnNov 25, 2022

Zydus Lifesciences Limited has informed the Exchange about related party transaction for the period ended September 2022 | Download

Zydus Lifesciences Limited has informed the Exchange about related party transaction for the period ended September 2022 | Download

Press Release 
Announced OnNov 23, 2022

Zydus Lifesciences Limited has informed the Exchange about press release dated 23-Nov-2022 titled Zydus receives final approval from the USFDA for Famotidine Injection | Download

Zydus Lifesciences Limited has informed the Exchange about press release dated 23-Nov-2022 titled Zydus receives final approval from the USFDA for Famotidine Injection | Download

Cash Dividend 
Ex. DateJul 28, 2022

Final • Div/Share: ₹ 2.5

See all events